Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report – Hagens Berman
Portfolio Pulse from
Regeneron Pharmaceuticals (REGN) is facing a securities class action lawsuit after its stock value dropped by $9 billion following its Q3 2024 earnings report. Investors with losses are encouraged to contact Hagens Berman before the March 10, 2025 deadline.
February 28, 2025 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regeneron Pharmaceuticals is facing a class action lawsuit due to a significant $9 billion loss in stock value after its Q3 2024 earnings report. Investors are advised to contact Hagens Berman by March 10, 2025.
The lawsuit and significant loss in stock value are likely to negatively impact investor sentiment and the stock price in the short term. Legal issues often create uncertainty, which can lead to further declines.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100